medi USA launches new drug-free treatment for Restless Legs Syndrome (RLS)

"RLS is a debilitating condition for an estimated 10% of the U.S. population, with many suffering from depression due to fatigue and quality of life issues," said Glenn Anderson, medi USA Director of Medical Category Management.  "The inability to sleep affects every aspect of their lives, as well as the lives of their loved ones."

"RLS is traditionally treated with powerful narcotics and opioids which may help to some degree but the problems encountered by the medications are oftentimes of equal or greater significance than the RLS," said Dr. John Sullivan, a neurologist based in Florida who was involved in restiffic's clinical trial.

Mary Sorg, the inventor and lifelong sufferer of RLS herself, has been working towards this for over a decade. "I just really want to help people with RLS. With restiffic, there's no medication. It's easy to use. It just works," she said. Mary was inspired to keep going over the years by the overwhelmingly positive results from restiffic's clinical trial, highlights of which include:

• Over 95% of patients had a significant reduction in RLS symptoms.
• Shown to be 40% more effective than the leading pharmaceutical treatment for RLS.
• Patients experienced a 69% reduction in RLS symptoms after six weeks of device usage.
• FDA cleared as a Class 1 device.

restiffic is available for purchase with a prescription at www.restiffic.com.

About medi USA

medi is the global leader in compression therapy, orthopedics, spinal bracing, prosthetics and foot care with over 60 years of experience producing and distributing medical devices.  To view the entire medi portfolio, visit www.mediusa.com. For more information and to order your restiffic please visit www.restiffic.com.

Media Contact
Maggie Moriarty
[email protected]
800-633-6334 x172

Video - http://youtu.be/Fe62f6qKGXc

SOURCE medi USA

Related Links

http://www.mediusa.com